NCT04240652 The Diabetic Retinopathy Screening, Prevention and Control Program
| NCT ID | NCT04240652 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Condition | Diabetic Retinopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 500,000 participants |
| Start Date | 2018-06-05 |
| Primary Completion | 2038-06-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500,000 participants in total. It began in 2018-06-05 with a primary completion date of 2038-06-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly; * Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study. Exclusion Criteria: * Those who have a history of drug abuse; * Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase; * Any condition that the investigator think that the subject is not suitable for participating in the study. For detailed In-/Ex-clusion criteria please see the study protocol.
Contact & Investigator
Guang Ning, MD,PHD
PRINCIPAL INVESTIGATOR
Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China
Frequently Asked Questions
Who can join the NCT04240652 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04240652 currently recruiting?
Yes, NCT04240652 is actively recruiting participants. Contact the research team at guangning@medmail.com.cn for enrollment information.
Where is the NCT04240652 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China.
Who is sponsoring the NCT04240652 clinical trial?
NCT04240652 is sponsored by Shanghai Jiao Tong University School of Medicine. The principal investigator is Guang Ning, MD,PHD at Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China. The trial plans to enroll 500,000 participants.